Articles tagged "Hepatitis C"

2019 American Transplant Congress
Evaluating Hepatitis C Treatment after Solid Organ Transplantation
A. J. Burgos¹, R. Yau¹, C. Tunwar², J. A. Goss³, S. Khaderi³, N. L. Sussman⁴
¹Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ²CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX, ³Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX, ⁴Abdominal Transplant & Liver Disease, Baylor College of Medicine, Houston, TX
*Purpose: There is limited data on the use of direct acting antivirals for hepatitis C virus (HCV) in the solid organ transplant (SOT) population. The…
2019 American Transplant Congress
Longer-Term Outcomes for Hepatitis C Virus Negative Recipients of Kidneys from Hepatitis C Virus Nucleic Acid Test Positive Donors: The THINKER Trial
P. Reese¹, P. Abt¹, E. Blumberg¹, R. Bloom¹, D. Sawinski¹, P. Porrett¹, A. Woodards¹, K. Reddy¹, V. van Deerlin¹, R. Hasz², M. Levine¹, R. McLean¹, A. Sicilia¹, D. Goldberg¹
¹University of Penn, Philadelphia, PA, ²Gift of Life, Philadelphia, PA
*Purpose: Two trials of transplanting hepatitis C virus (HCV) nucleic acid test (NAT) positive kidneys into HCV-negative recipients have been published, both with 100% HCV…
2019 American Transplant Congress
Donate HCV Trial: Transplanting Thoracic Organs from Hepatitis C Donors to Uninfected Patients
A. E. Woolley¹, S. K. Singh², H. J. Goldberg³, M. M. Givertz⁴, M. R. Mehra⁴, A. Coppolino, III⁵, V. Cheng¹, J. Fanikos⁶, D. P. Harrington⁷, H. R. Mallidi², L. R. Baden¹
¹Infectious Diseases, Brigham and Womens Hospital, Boston, MA, ²Cardiac and Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, ³Pulmonary, Brigham and Womens Hospital, Boston, MA, ⁴Cardiology, Brigham and Womens Hospital, Boston, MA, ⁵Thoracic Surgery, Brigham and Womens Hospital, Boston, MA, ⁶Pharmacy, Brigham and Womens Hospital, Boston, MA, ⁷Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
*Purpose: Given the need for thoracic organs and the high mortality of patients awaiting heart or lung transplantation, it is imperative to find ways to…
2019 American Transplant Congress
Listing Practices and Graft Utilization Lag behind Supply of Hepatitis C Positive Deceased Donors for Liver and Kidney Transplant
C. E. Kling¹, J. D. Perkins², S. W. Biggins³, C. Johnson⁴, A. P. Limaye⁵, L. Sibulesky¹
¹Division of Transplant Surgery, University of Washington Medical Center, Seattle, WA, ²Division of Transplant Surgery and Clinical and Bio-Analytics Transplant Laboratory, University of Washington Medical Center, Seattle, WA, ³Divisions of Gastroenterology and Hepatology and Center for Liver Investigation Fostering DiscovEry, University of Washington Medical Center, Seattle, WA, ⁴Division of Nephrology, University of Washington Medical Center, Seattle, WA, ⁵Division of Infectious Disease, University of Washington Medical Center, Seattle, WA
*Purpose: The opioid epidemic resulted in increasing incidence of hepatitis C (HCV) in the general population and more deceased organ donors with HCV in the…
2019 American Transplant Congress
Transplantation of Kidneys from Hepatitis C Infected Donors to Hepatitis C Negative Recipients
M. Z. Molnar, O. Cseprekal, M. Yazawa, M. Talwar, V. Balaraman, V. Mas, D. Maluf, R. Helmick, L. Campos, N. Nezakatgoo, C. Eymard, P. Horton, R. Verma, A. Jenkins, C. R. Handley, H. Snyder, C. Cummings, U. A. Agbim, B. Maliakkal, S. K. Satapathy, S. P. Nair, J. D. Eason
Methodist University Hospital Transplant Institute, Memphis, TN
*Purpose: There are no data on the safety of kidney transplantation from hepatitis C (HCV) NAT positive donors to HCV naïve recipients. We report the…
2019 American Transplant Congress
Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease
M. Yoshikawa¹, T. Fukumoto²
¹Nephrology, Kobe University Hospital, Kobe, Japan, ²Hepato-Biliary-Pancreas Surgery, Kobe University Hospital, Kobe, Japan
*Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…
2019 American Transplant Congress
Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation
J. Wellington¹, A. Ma², S. Kottilil³, J. Husson³, E. Wilson³, D. Bruno⁴
¹Gastroenterology & Hepatology, University of Maryland, Baltimore, MD, ²Internal Medicine, University of Maryland, Baltimore, MD, ³Institute of Human Virology, Division of Clinical Care and Research, University of Maryland, Baltimore, MD, ⁴Transplant Surgery, University of Maryland, Baltimore, MD
*Purpose: Liver transplantation, LT, for HCV-related disease has the lowest five-year graft survival of all LT recipients, primarily due to accelerated fibrosis from unrestrained HCV…
2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
2019 American Transplant Congress
Recipient Sex Interacts with Primary Diagnosis to Affect Liver Transplant Graft Survival
D. Yoeli¹, R. Choudhury¹, H. Moore¹, M. Simpson², A. Sauaia¹, E. Pomfret¹, T. Nydam¹
¹Surgery, University of Colorado, Denver, CO, ²Surgery, Lahey Clinic, Burlington, MA
*Purpose: While recipient sex is a commonly studied risk factor in liver transplantation, findings have been contradictory. We hypothesized that different causes of liver disease…
2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…